Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

The approvals were based on results from a phase 2 trial and a phase 3 trial. The US Food and Drug Administration (FDA) has approved the PD-1 inhibitor penpulimab-kcqx for 2 indications ...

A retrospective analysis showed higher response rate for cabozantinib/nivolumab vs. lenvatinib/pembrolizumab in advanced RCC, with no significant survival or safety differences. A retrospective ...